EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Defining a critical therapeutic window: cyclosporine exposure in months 1–2 as a determinant of acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation from matched related donors

Neslihan Hazel Önür, Vildan Özkocaman, Fahir Özkalemkaş

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-07131-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Neslihan Hazel Önür und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Bursa, Türkiye. nh.onur@istanbul.edu.tr. Hauptthemen laut MEDLINE: Cyclosporine, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Immunosuppressive Agents. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bursa Uludag University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute graft-versus-host disease (aGVHD) is one of the most fatal yet preventable complications of hematopoietic stem cell transplantation (HSCT). Identifying optimal cyclosporine (CsA) blood level thresholds is particularly important in patients receiving CsA-based prophylaxis; however, cut-off values remain unclear. This retrospective study evaluated 120 patients with acute leukemia (64% acute myeloid leukemia [AML], 36% acute lymphoblastic leukemia [ALL]) who underwent allogeneic HSCT (AHSCT) between June 2011 and March 2021. CsA combined with methotrexate was used for GVHD prophylaxis. Statistical analyses included ROC analysis to determine optimal cut-off values and logistic regression to identify independent risk factors for aGVHD. aGVHD developed in 34 patients (28%), with a median onset at day 48. ROC curve analysis identified a CsA cut-off level of 274 µg/L during months 1–2, with an AUC of 0.697 (95% Confidence Interval [CI]: 0.574–0.820, p = 0.005), sensitivity of 77.3%, and specificity of 63%. In multivariate analysis, higher CsA levels during months 1–2 (Odds Ratio [OR] = 0.990, 95% CI 0.981–1.000; p = 0.039) and pre-transplant steroid use (OR = 0.284, 95% CI 0.094–0.860; p = 0.026) were independently associated with reduced risk of aGVHD. No universally accepted cut-off value of CsA levels has been defined to date, and our findings suggest that maintaining levels above 274 µg/L during the first 1–2 months post-transplant is critical to reduce aGVHD risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclosporineGraft vs Host DiseaseHematopoietic Stem Cell TransplantationImmunosuppressive AgentsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaHumansFemaleMaleAdultRetrospective StudiesMiddle AgedTransplantation, HomologousYoung AdultAdolescentAcute DiseaseAgedTissue DonorsRisk FactorsTime Factors

Stichwörter der Autor:innen

Acute graft-versus-host diseaseAcute leukemiaAllogeneic hematopoietic stem cell transplantationCyclosporine

Substanzen

CyclosporineImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Bursa, Türkiye. nh.onur@istanbul.edu.tr.
  • Division of Geriatrics, Department of Internal Medicine, Istanbul University Fatih, Istanbul, Türkiye. nh.onur@istanbul.edu.tr.
  • Division of Hematology, Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Bursa, Türkiye.

Förderung

  • Bursa Uludag University

Zitieren

APA

Önür, N. H., Özkocaman, V., & Özkalemkaş, F. (2026). Defining a critical therapeutic window: cyclosporine exposure in months 1–2 as a determinant of acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation from matched related donors. Annals of Hematology. https://doi.org/10.1007/s00277-026-07131-9

Vancouver

Önür NH, Özkocaman V, Özkalemkaş F. Defining a critical therapeutic window: cyclosporine exposure in months 1–2 as a determinant of acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation from matched related donors. Annals of Hematology. 2026. doi:10.1007/s00277-026-07131-9

BibTeX
@article{nr2026,
  author = {Önür, Neslihan Hazel and Özkocaman, Vildan and Özkalemkaş, Fahir},
  title = {Defining a critical therapeutic window: cyclosporine exposure in months 1–2 as a determinant of acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation from matched related donors},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07131-9}
}
Kostenlos starten →